<DOC>
	<DOCNO>NCT01406548</DOCNO>
	<brief_summary>This study design provide information safety , tolerability , pharmacokinetics ( PK ) bone biomarker response follow multiple BPS804 administration multiple dose regimen . This information permit comparison possible risk benefit different dose regimen study drug enable optimal dos dose interval test subsequent study .</brief_summary>
	<brief_title>Safety Efficacy Multiple Dosing Regimens BPS804 Post Menopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Postmenopausal woman ( natural surgically induced menopause ) Low bone mineral density ( BMD ) , define T score equivalent BMD absolute value ( g/cm2 ) lumbar spine 2.0 3.5 , inclusive Body mass index ( BMI ) must within range 18 35kg/m2 . Subjects must weigh 45 120kg inclusive participate . 25 ( OH ) vitamin D serum level â‰¥ 15ng/ml Serum calcium within normal limit Subjects suspect neural foraminal stenosis ( e.g. , cervical , spinal , lumbar ) , history Bell 's palsy , cranial nerve disorder , temporomandibular joint muscle disorder . Subjects increase baseline risk osteosarcoma : Paget 's disease bone unexplained clinically significant elevation alkaline phosphatase and/or subject receive radiation therapy involve skeleton . Subjects know bone diseases postmenopausal osteoporosis . Subjects history osteoporotic fracture ( e.g. , vertebral fracture , fragility fracture wrist , radius , humerus , hip , pelvis ) . Subjects regularly use regularly use agent affect bone metabolism : Calcitonin , estrogen , SERMs ( raloxifene , Tamoxifen , etc . ) , Tibolone progestin , androgens within last three ( 3 ) month prior screen . Any oral bisphosphonate , lithium chloride , fluoride systemic glucocorticosteroids ( p.o . i.v . ) total dose exceed 750 mg prednisone equivalent within last year prior screen . Any previous use denusomab ( ProliaTM ) , parathyroid hormone ( ForteoTM ) , and/or PTH analog , strontium ranelate , parenteral formulation bisphosphonates . Current disease ( ) know influence calcium metabolism include hyperparathyroidism , hypoparathyroidism , hypocalcemia hypercalcemia . Any disease , abnormality deformation spine ( e.g. , scoliosis , ankylose spondylitis , osteophytes ) hip ( e.g. , joint prosthesis ) would preclude proper acquisition lumbar spine DXA ( L1L4 ) femur DXA , respectively . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Osteopenia</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>low bone mineral density</keyword>
</DOC>